WallStreetZenWallStreetZen

NASDAQ: IMPL
Impel Pharmaceuticals Inc Stock

$0.52-0.08 (-13.33%)
Updated Nov 29, 2023
IMPL Price
$0.52
Fair Value Price
N/A
Market Cap
$12.45M
52 Week Low
$0.19
52 Week High
$4.20
P/E
-0.17x
P/B
-0.14x
P/S
0.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$20.99M
Earnings
-$74.28M
Gross Margin
52.6%
Operating Margin
-294.96%
Profit Margin
-353.9%
Debt to Equity
-1.38
Operating Cash Flow
-$79M
Beta
0.97
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

IMPL Overview

Impel NeuroPharma Incorporated is developing therapies for patients suffering from central nervous system diseases. The company's pipeline includes TRUDHESA, an upper nasal formulation of dihydroergotamine for the treatment of migraines, INP105, an upper nasal formulation of olanzapine for the treatment of agitation and aggression in autism spectrum disorder, and INP107, an upper nasal formulation of Carbidopa/Levodopa. Impel NeuroPharma was incorporated in 2008 and is headquartered in Seattle, WA.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMPL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IMPL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IMPL is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
IMPL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more IMPL due diligence checks available for Premium users.

Be the first to know about important IMPL news, forecast changes, insider trades & much more!

IMPL News

Valuation

IMPL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.17x
Industry
12.91x
Market
29.48x

IMPL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.14x
Industry
5.35x

IMPL's financial health

Profit margin

Revenue
$5.0M
Net Income
-$13.8M
Profit Margin
-275%
IMPL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IMPL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$35.1M
Liabilities
$127.0M
Debt to equity
-1.38
IMPL's short-term liabilities ($124.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMPL's short-term assets ($23.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMPL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMPL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$16.5M
Investing
-$957.0k
Financing
$7.1M
IMPL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IMPL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
IMPL$12.45M-12.88%-0.17x-0.14x
ASLN$12.35M+5.59%-0.26x-14.01x
TNXP$12.28M+5.53%-0.06x0.10x
AZTR$12.70M-3.67%N/A2.38x
NRSN$12.78M+15.82%-1.09x-65.18x

Impel Pharmaceuticals Stock FAQ

What is Impel Pharmaceuticals's quote symbol?

(NASDAQ: IMPL) Impel Pharmaceuticals trades on the NASDAQ under the ticker symbol IMPL. Impel Pharmaceuticals stock quotes can also be displayed as NASDAQ: IMPL.

If you're new to stock investing, here's how to buy Impel Pharmaceuticals stock.

What is the 52 week high and low for Impel Pharmaceuticals (NASDAQ: IMPL)?

(NASDAQ: IMPL) Impel Pharmaceuticals's 52-week high was $4.20, and its 52-week low was $0.19. It is currently -87.6% from its 52-week high and 174.21% from its 52-week low.

How much is Impel Pharmaceuticals stock worth today?

(NASDAQ: IMPL) Impel Pharmaceuticals currently has 23,900,031 outstanding shares. With Impel Pharmaceuticals stock trading at $0.52 per share, the total value of Impel Pharmaceuticals stock (market capitalization) is $12.45M.

Impel Pharmaceuticals stock was originally listed at a price of $15.00 in Apr 23, 2021. If you had invested in Impel Pharmaceuticals stock at $15.00, your return over the last 2 years would have been -96.53%, for an annualized return of -81.36% (not including any dividends or dividend reinvestments).

How much is Impel Pharmaceuticals's stock price per share?

(NASDAQ: IMPL) Impel Pharmaceuticals stock price per share is $0.52 today (as of Nov 29, 2023).

What is Impel Pharmaceuticals's Market Cap?

(NASDAQ: IMPL) Impel Pharmaceuticals's market cap is $12.45M, as of Dec 1, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Impel Pharmaceuticals's market cap is calculated by multiplying IMPL's current stock price of $0.52 by IMPL's total outstanding shares of 23,900,031.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.